simendan has been researched along with omecamtiv mecarbil in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cas, LD; Cotter, G; Gheorghiade, M; Metra, M; Sabbah, HN; Teerlink, JR; Zacà, V | 1 |
| Campia, U; Gheorghiade, M; Nodari, S | 1 |
| Fox, CJ; Kaye, AD; Liu, H; Zhang, S | 1 |
| Pollesello, P | 1 |
| Anker, SD; Balligand, JL; Bauersachs, J; Brutsaert, D; Carrier, L; Chlopicki, S; Cleland, JG; de Boer, RA; de Keulenaer, G; Dietl, A; Eschenhagen, T; Fischmeister, R; Hamdani, N; Harjola, VP; Heinzel, FR; Heymans, S; Hilfiker-Kleiner, D; Holzmeister, J; Limongelli, G; Linke, WA; Lund, LH; Lyon, AR; Maack, C; Manstein, DJ; Masip, J; Mebazaa, A; Metra, M; Metzger, J; Mueller, C; Papp, Z; Pieske, B; Ponikowski, P; Ristić, A; Ruschitzka, F; Seferović, PM; Skouri, H; Tocchetti, CG; Yilmaz, MB; Zimmermann, WH | 1 |
| Borbély, A; Csanádi, Z; Édes, I; Horváth, B; Nánási, PP; Papp, Z; Ráduly, AP; Sárkány, F; Szentandrássy, N; Tóth, A | 1 |
2 review(s) available for simendan and omecamtiv mecarbil
| Article | Year |
|---|---|
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failure; Hemodynamics; Hospitals, Group Practice; Humans; Hydrazones; Prognosis; Pyrazines; Pyridazines; Quinolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Treatment Outcome; Urea; Vasodilator Agents | 2009 |
Cardiovascular pharmacology: an update.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Diastole; Heart Failure; Humans; Hydrazones; Muscle Contraction; Myofibrils; Natriuretic Peptide, Brain; Nicardipine; Pyridazines; Pyridines; Sarcomeres; Simendan; Urea | 2010 |
4 other study(ies) available for simendan and omecamtiv mecarbil
| Article | Year |
|---|---|
Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?
Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Dobutamine; Etiocholanolone; Genetic Therapy; Heart Failure; Humans; Hydrazones; Pyridazines; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Potassium-Exchanging ATPase; Urea | 2010 |
Drug discovery and development for acute heart failure drugs: are expectations too high?
Topics: Acute Disease; Cardiotonic Agents; Clinical Trials as Topic; Drug Discovery; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan; Urea | 2014 |
Treatments targeting inotropy.
Topics: Acute Disease; Animals; Antioxidants; Calcium; Cardiotonic Agents; Case-Control Studies; Catecholamines; Clinical Trials as Topic; Diastole; Dobutamine; Dogs; Energy Metabolism; Excitation Contraction Coupling; Heart Failure; Humans; Mitochondria; Models, Animal; Myocardial Contraction; Nitrogen Oxides; Oxidation-Reduction; Phosphodiesterase Inhibitors; Placebos; Receptors, Adrenergic; Sarcomeres; Shock, Cardiogenic; Simendan; Swine; Systole; Urea | 2019 |
Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca
Topics: Animals; Dogs; Heart Failure; Myocytes, Cardiac; Myosins; Simendan; Stroke Volume | 2023 |